GSK3915393

GSK3915393 is an investigational small molecule inhibitor of transglutaminase 2 (TG2), developed by GSK. It is being studied primarily for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease characterized by progressive scarring of lung tissue, and has also been evaluated in early clinical studies for celiac disease. The drug works by inhibiting TG2, an enzyme implicated in both fibrotic processes and the modification of gluten peptides that trigger immune responses in celiac disease. Clinical trials have assessed its safety, tolerability, pharmacokinetics, and efficacy via oral and intravenous administration[1][2][5][6][7].